Minimal residual disease in chronic lymphocytic leukemia: A consensus paper that presents the clinical impact of the presently available laboratory approaches.

摘要: Chronic lymphocytic leukemia (CLL) is a malignancy defined by the accumulation of mature lymphocytes in lymphoid tissues, bone marrow, and blood. Therapy for CLL guided according to Rai Binet staging systems. Nevertheless, state-of-the-art protocols disease monitoring, diagnostics, prognostics are based on assessment minimal residual (MRD). MRD internationally considered be level that can detected sensitive techniques represents incomplete treatment probability relapse. detection has been continuously improved quick development both flow cytometry molecular biology technology, as well next-generation sequencing. Considering moving more from research clinical practice, where it an independent prognostic marker, this paper, we present methodologies which evaluated, translational practice.